SEK 5.64
(-1.05%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 58.06 Million SEK | -4.46% |
2022 | 60.77 Million SEK | 152.8% |
2021 | 24.04 Million SEK | -12.72% |
2020 | 27.54 Million SEK | 14.45% |
2019 | 24.06 Million SEK | -19.1% |
2018 | 29.74 Million SEK | 16.33% |
2017 | 25.57 Million SEK | 4.63% |
2016 | 24.44 Million SEK | 1126.44% |
2015 | 1.99 Million SEK | -10.94% |
2014 | 2.23 Million SEK | 91.47% |
2013 | 1.16 Million SEK | -6.29% |
2012 | 1.24 Million SEK | -67.12% |
2011 | 3.79 Million SEK | -5.82% |
2010 | 4.02 Million SEK | -11.76% |
2009 | 4.56 Million SEK | -5.42% |
2008 | 4.82 Million SEK | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 56.87 Million SEK | -2.05% |
2024 Q2 | 73.5 Million SEK | 29.24% |
2023 FY | 58.06 Million SEK | -4.46% |
2023 Q4 | 58.06 Million SEK | -0.41% |
2023 Q1 | 53.51 Million SEK | -11.94% |
2023 Q2 | 58.72 Million SEK | 9.73% |
2023 Q3 | 58.3 Million SEK | -0.72% |
2022 Q3 | 274.08 Million SEK | 594.25% |
2022 Q4 | 60.77 Million SEK | -77.83% |
2022 Q1 | 23.19 Million SEK | -3.54% |
2022 FY | 60.77 Million SEK | 152.8% |
2022 Q2 | 39.48 Million SEK | 70.23% |
2021 FY | 24.04 Million SEK | -12.72% |
2021 Q2 | 22.69 Million SEK | 2.0% |
2021 Q1 | 22.24 Million SEK | -19.24% |
2021 Q3 | 20.76 Million SEK | -8.52% |
2021 Q4 | 24.04 Million SEK | 15.8% |
2020 Q2 | 21.99 Million SEK | 2.0% |
2020 Q1 | 21.56 Million SEK | -10.39% |
2020 FY | 27.54 Million SEK | 14.45% |
2020 Q4 | 27.54 Million SEK | 17.84% |
2020 Q3 | 23.37 Million SEK | 6.26% |
2019 Q4 | 24.06 Million SEK | 3.44% |
2019 FY | 24.06 Million SEK | -19.1% |
2019 Q2 | 24.19 Million SEK | -6.88% |
2019 Q1 | 25.98 Million SEK | -12.66% |
2019 Q3 | 23.26 Million SEK | -3.84% |
2018 Q3 | 24.63 Million SEK | -5.74% |
2018 Q2 | 26.13 Million SEK | 1.87% |
2018 FY | 29.74 Million SEK | 16.33% |
2018 Q4 | 29.74 Million SEK | 20.77% |
2018 Q1 | 25.65 Million SEK | 0.31% |
2017 Q1 | 23.66 Million SEK | -3.18% |
2017 Q2 | 23.8 Million SEK | 0.6% |
2017 Q3 | 24.68 Million SEK | 3.68% |
2017 Q4 | 25.57 Million SEK | 3.62% |
2017 FY | 25.57 Million SEK | 4.63% |
2016 Q4 | 24.44 Million SEK | 0.44% |
2016 Q3 | 24.33 Million SEK | -11.25% |
2016 FY | 24.44 Million SEK | 1126.44% |
2016 Q2 | 27.42 Million SEK | 1144.75% |
2016 Q1 | 2.2 Million SEK | 10.54% |
2015 FY | 1.99 Million SEK | -10.94% |
2015 Q3 | 2.2 Million SEK | 3.46% |
2015 Q4 | 1.99 Million SEK | -9.58% |
2015 Q1 | 1.07 Million SEK | -52.0% |
2015 Q2 | 2.13 Million SEK | 98.32% |
2014 FY | 2.23 Million SEK | 91.47% |
2014 Q4 | 2.23 Million SEK | 78.0% |
2014 Q3 | 1.25 Million SEK | 23.01% |
2014 Q2 | 1.02 Million SEK | 0.0% |
2014 Q1 | - SEK | -100.0% |
2013 Q4 | 1.16 Million SEK | 0.0% |
2013 Q2 | 2.53 Million SEK | 0.0% |
2013 Q1 | 2.53 Million SEK | 103.09% |
2013 FY | 1.16 Million SEK | -6.29% |
2012 Q4 | 1.24 Million SEK | 0.0% |
2012 FY | 1.24 Million SEK | -67.12% |
2012 Q2 | 1.24 Million SEK | 0.0% |
2011 FY | 3.79 Million SEK | -5.82% |
2011 Q4 | 3.79 Million SEK | 0.0% |
2011 Q2 | 3.75 Million SEK | 0.0% |
2010 Q4 | 4.02 Million SEK | 0.0% |
2010 Q2 | 4.12 Million SEK | 0.0% |
2010 FY | 4.02 Million SEK | -11.76% |
2009 Q4 | 4.56 Million SEK | 0.0% |
2009 FY | 4.56 Million SEK | -5.42% |
2008 FY | 4.82 Million SEK | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Acarix AB (publ) | 10.99 Million SEK | -427.96% |
ADDvise Group AB (publ) | 2.67 Billion SEK | 97.829% |
ADDvise Group AB (publ) | 2.67 Billion SEK | 97.829% |
Arcoma AB | 33.3 Million SEK | -74.343% |
Bactiguard Holding AB (publ) | 329.7 Million SEK | 82.389% |
BICO Group AB (publ) | 3.26 Billion SEK | 98.221% |
Boule Diagnostics AB (publ) | 279.9 Million SEK | 79.255% |
CellaVision AB (publ) | 212.32 Million SEK | 72.653% |
Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -308.995% |
Chordate Medical Holding AB (publ) | 6.86 Million SEK | -745.327% |
C-Rad AB (publ) | 122.4 Million SEK | 52.561% |
Duearity AB (publ) | 17.53 Million SEK | -231.232% |
Dignitana AB (publ) | 37.56 Million SEK | -54.564% |
Episurf Medical AB (publ) | 19.8 Million SEK | -193.258% |
Getinge AB (publ) | 24.69 Billion SEK | 99.765% |
Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -181.865% |
Iconovo AB (publ) | 14.55 Million SEK | -298.965% |
Integrum AB (publ) | 22.07 Million SEK | -163.061% |
Luxbright AB (publ) | 7 Million SEK | -729.486% |
Mentice AB (publ) | 163.55 Million SEK | 64.498% |
OssDsign AB (publ) | 105.25 Million SEK | 44.835% |
Paxman AB (publ) | 44.5 Million SEK | -30.457% |
Promimic AB (publ) | 16.15 Million SEK | -259.402% |
Qlife Holding AB (publ) | 62.16 Million SEK | 6.601% |
SciBase Holding AB (publ) | 21.27 Million SEK | -172.887% |
ScandiDos AB (publ) | 37.18 Million SEK | -56.147% |
Sectra AB (publ) | 1.64 Billion SEK | 96.462% |
Sedana Medical AB (publ) | 44.06 Million SEK | -31.78% |
SpectraCure AB (publ) | 14.97 Million SEK | -287.746% |
Stille AB | 172.64 Million SEK | 66.366% |
Vitrolife AB (publ) | 3.66 Billion SEK | 98.417% |
Xvivo Perfusion AB (publ) | 250.56 Million SEK | 76.826% |